人参二苓汤联合培美曲赛、卡铂治疗晚期非小细胞肺癌46例临床观察

The Clinical Observation of Renshenerling Decoction Integrated with Pemetrexed and Carboplatin in the Treatment of 40 Patients with Advanced Non-small Cell Lung Cancer

[目的]观察人参二苓汤联合培美曲赛加卡铂化疗在治疗晚期非小细胞肺癌(Non-small cell lung cancer,NSCLC)的疗效和不良反应。[方法]收集2009年1月至2011年6月晚期NSCLC 46例,随机分成治疗组和对照组,对照组予以培美曲赛500mg/m2体表面积第1d加卡铂300mg/m2体表面积第1d化疗,21d为1个周期;治疗组在培美曲赛加卡铂化疗同时加服人参二苓汤,4个周期后比较两组的疗效及不良反应。[结果]治疗组和对照组在治疗晚期NSCLC疗效相似(P>0.05),但在不良反应方面,治疗组在白细胞减少、恶心呕吐、乏力、皮疹方面明显低于对照组(P<0.05)。[结论]人参二苓汤联合培美曲赛加卡铂化疗在治疗晚期NSCLC确有增强解毒功效,值得在临床上推广应用。

[Objective] To observe the clinical effect and side-effect of Renshenerling decoction integrated with Pemetrexed combined with Carboplatin and Pemetrexed combined with Carboplatin only in the treatment of 40 patients with advanced non-small cell lung cancer.[Methods] 46 cases with advanced non-small cell lung cancer were randomly divided into the treatment group and the contrast group.The treatment group was treated by Renshenerling decoction integrated with Pemetrexed combined with Carboplatin and contrast group by Pemetrexed combined with Carboplatin only.Chemotherapy consisted of Pemetrexed 500mg/M2 d1 combined with Carboplatin 300mg/M2 d1 of a 21-day cycle.All patients received 4 cycles at least.The effect and side-effect in both groups were observed and compared.[Result] The effective rates in both groups were similar.While leukopenia,nausea and vomiting,lack of power,rash in treatment group was obviously less than that in the contrast group.[Conclusion] Renshenerling decoction integrated with Pemetrexed combined with Carboplatin can increase the detoxification function in patients with advanced non-small cell lung cancer.